Biom Designer Microbiome
We are developing Longevity-Enhancing Designer Microbiome. Our blue-zone microbiome project delineate longevity Enhancing microbiome
Microbiome Diversifying Complex(MDC) expands microbiome metabolic potential by modulating gene expression and producing longevity-enhancing metabolites
Our microbiome cataloguing and storing service. We study and track your Healthy microbiome when You are in the prime of your health so that you can use it as you age or succumb to carious disease conditions
OUR R & D TECHNOLOGY PROJECTS
Microbiome Therapy Against Antibiotic “Resistant Microbes”
The threat of Anti Microbial Resistance (AMR) is growing at an alarming rate with an estimated near-future global toll of 10 million deaths per year. Recent studies suggest that the two major reservoirs of resistance genes (‘called resistomes’) reside in human commensals (fecal origin) and in the soil microbiota (environment origin). Human microbiome modulation is an effective way to control AMR bacteria.
We are developing designer human microbiome therapy against antibiotic resistant strains of bacteria and already partnered up with leading academic institutions to jointly develop technolgoies to tackle this global challenge.
BiomSAFETM:Microbiome Cataloging and Banking Service
Biom Pharma is developing human microbiome biobanking, BiomSafe, as a premier microbiome service. Realizing the importance of microbiome in personal health and well-being, there is strong market need from customers to store and catalogue their microbiome for wellness and therapeutic purposes. However, no company is offering a comprehensive personalized microbiome-based wellness solution.
We provide the microbiome banking as a long-term proactive health care service for personalized health and well-being. We also developed proprietary technologies to expand and make ‘humanized designer’ version of your microbiome based on different parameters such as dietary changes, health supplement-adapted, and other medications adapted (NSAIDS, painkillers etc). Further, we leverage our strength in microbiome to design new microbiome therapeutics for various disease conditions and indications.
Natural Product Discovery from Human Microbiome
Advances in DNA sequencing technologies and the accompanying increase in the available (meta)genomic sequencing data have enabled computational strategies for natural product discovery. Genome mining approaches take advantage of the fact that the genes responsible for constructing microbial secondary metabolites are typically co-localized in biosynthetic gene clusters (BGCs). Automated programs such as ClusterFinder, a hidden Markov model-based probabilistic algorithm, have been developed to rapidly and accurately identify BGCs from DNA sequencing data. Recently, several studies identified more than 14,000 BGCs from HMP reference genomes. These human-associated BGCs are predicted to synthesize a broad range of natural product classes, including saccharides, NRPs, PKs, and ribosomally encoded and post-translationally modified peptides (RiPPs).
A recent analysis of genomic and metagenomic sequencing data from the Human Microbiome Project (HMP) showed that human-associated bacteria encode the biosynthetic machinery to synthesize a vast array of secondary metabolites. However, the identities of nearly all of these natural products are unknown, and their biological roles are not well understood. Uncovering the mechanisms by which these molecules mediate host-microbe and microbe-microbe interactions could reveal factors influencing the microbiome’s effect on the host, a source of narrow-spectrum therapeutics, and inspire new strategies for treating human disease.
Our understanding of the structures and functions of natural products made by the human microbiome is in its infancy. The case studies highlighted here showcase the utility of multiple approaches for identifying and characterizing microbiota-derived metabolites. Integrating additional emerging strategies for natural product discovery into such efforts, such as synthetic refactoring of cryptic BGCs and elicitation of cryptic gene cluster expression by small molecules (62), should enable the discovery of additional bioactive secondary metabolites from the human microbiome.
At Biom. Our team of scientist are analyzing and purifying health benefit prompting secondary microbiome metabolities using our microbiome ex-vivo culture system.
Microbiome as delivery platform for in Personalized Gene and Cancer Therapy
Human microbiome has high degree of plasticity than human genome with tremendous gene pool potential. Microbiome can be adapted and evolved via external interventions and modifications (e.g. CrispR, targeted evolution). The efficacy of personalized gene therapy as a precision medicine to prevent or treat several cancers are becoming clinically very evident. Microbiome modulation can augment this sector both as intervention and novel delivery platform.
Microbiome Therapy Against Enteric Pathogens
Foodborne diseases result in a large disease burden, particularly in children. Enteric infections, with or without overt diarrhea, have profound effects on global mortality. The absorptive function of a healthy intestinal tract is especially critical in the first few formative years of life. This is because, unlike many other species, the predominant brain and synapse development in humans occurs in the first 2 years after birth. Hence, the absorption of key nutrients during this time is critical to assure the optimal growth and development of the body, brain, and neuronal synapses that determine human capacity.
Enteric pathogens that are the cause of most severe acute diarrhea — as assessed by mortality — include rotavirus, Vibrio cholerae, Shigella spp., Salmonella spp., enteropathogenic E. coli (EPEC), and EAEC.
Biom Pharma is developing vaccines using our designer microbiome technology which include both bacterial and phage-based platform.
Microbiome Therapy for Neurological Disorders
Neuropsychiatric disorder are on the increase globally and, of the noncommunicable diseases, stand out as a leading cause of disability. Accruing evidence strongly links gut dysbiosis (gut microbiota–host maladaptation) as a risk factor in a wide range of mental illnesses that include neuropsychiatric conditions such as autism spectrum disorder (ASD), Alzheimer’s disease, epilepsy and schizophrenia among them. There are currently no drugs approved that treat the core symptoms of ASD.
We are creating lines of designer microbiomes with signature species and specific metabolic profile to enhance neurological pathologies of these dieseases.
Microbiome Modulation For Senolytic and Longevity Functions
A long healthy life-span is everybody dream. A long human life span – exceeding eight decades or more – is becoming increasingly attainable in the developed countries. The remarkable increase in lifespan enjoyed by modern humans is due to major advances in preventing, delaying or curing individual pathologies such as infections, hypertension, type 2 diabetes, and even some forms of cancer.
The challenge now is to promote health span and to reduce the duration and severity of morbidity that precedes death. High incidence of diseases such as Alzheimer’s is a Damocles sword in the effort to increase human life span. It is estimated that by 2030, there will be 56 million cases of Alzheimer’s diseases patients!
Human commensal microbiota develop and evolves with us from our birth. The intestinal microbiota is probably the most adaptive component of the human being, allowing for the optimization of its host’s physiology from daily life circumstances to increased life span scales and human evolution. It eventually becomes a vital organ called “core microbiome” optimized for our specific diet, genetic background and life style. Our core microbiome determines our disease resistance physiology and longevity patterns.
Extreme-age people – centenarians – have a microbiota that differs from those of older adults and their key microbiome metabolite profile is also unique. The healthy diet diversity index positively correlated with three microbiota diversity indices. Loss of core microbiome with age with changes in key microbiome metabolite production is a key step which accelerates aging process. We are developing microbiome diversifying and longevity-enhancing secondary metabolite production technologies for several age-groups.
Microbiome in Stem Cell Modulation
Stem cells are integral component of human body and its turnover is critical for many physiological processes. Newest studies have that the hypothalamus, with an important role in cognitive function and aging, generates new neurons from neural stem cells. Killing hypothalamic neural stem cells accelerates aging, and transplantation additional neural stem cells into the brain region slows it down. Core microbiome plays an important role in the stem cells turnover of various organ rejuvenation. We are identifying the important role microbiome metabolites play stem cell biology in human body